Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.

Viking Therapeutics has announced positive results from its Phase Ib trial of VK0214 in patients with X-linked ...

Viking Therapeutics (VKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test ...

Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often ...

On Wednesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released data from the Phase 1b trial of VK0214, a novel small molecule ...

Viking Therapeutics Inc.'s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...

If you are considering of Buying or Selling, Letting or Renting or any aspects of the property market such as residential, ...

Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...